Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243003 | 0.77 | CYP2D6 (0.67) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL12758895 | 0.76 | CHRNB2 (0.40) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL12758911 | 0.74 | CDK4 (0.44) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL1732446 | 0.73 | CYP2D6 (0.65) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL7015581 | 0.72 | CYP3A4 (0.57) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL12758899 | 0.72 | CHRNB2 (0.37) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL1426895 | 0.71 | ALDH1A1 (0.50) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL14218795 | 0.70 | CYP2D6 (0.60) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL18497991 | 0.70 | CYP2D6 (0.55) | CYP2D6CYP3A4TSHRUSP2CYP1A2 | |
| SCHEMBL16349557 | 0.69 | CYP2D6 (0.59) | CYP2D6CYP3A4TSHRUSP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MCHR2, MCHR1, ADRB2 | KCNH2 499/4885CYP2D6 74/4885CYP3A4 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.